BioLineRx Reports Promising Motixafortide Combo Data In PDAC Ahead Of ASCO 2025

BioLineRx (BLRX) announced positive updated results from the pilot phase of its Phase 2 CheMo4METPANC trial, showing that motixafortide, combined with cemiplimab and chemotherapy, significantly improved outcomes in first-line metastatic pancreatic cancer, with a 64% overall response rate versus 23% historically with chemotherapy alone. The study has been expanded to a randomized design with increased enrollment, and an interim analysis is planned; in response, BLRX is currently trading up nearly 82%.

Analysis

BioLineRx (BLRX) has reported highly encouraging updated results from the pilot phase (n=11) of its Phase 2 CheMo4METPANC trial for motixafortide in first-line metastatic pancreatic ductal adenocarcinoma (PDAC). The combination therapy, involving motixafortide, PD-1 inhibitor cemiplimab, and standard chemotherapy, achieved a 64% overall response rate (ORR) and a 91% disease control rate (DCR). These figures represent a significant improvement over historical response rates for chemotherapy alone, which stand at 23% ORR and 48% DCR. Notably, within the pilot cohort, 4 of 11 patients experienced progression-free survival exceeding one year, and two patients responded sufficiently to undergo definitive treatments such as radiation and surgery. Biomarker analysis further supports the drug's mechanism, revealing enhanced CD8+ T-cell infiltration in tumors post-treatment and identifying pre-treatment levels of CXCL12-producing cancer-associated fibroblasts as a potential biomarker for patient response. Based on these promising findings, BioLineRx is expanding the study into a randomized trial, increasing patient enrollment from 30 to 108, with full enrollment anticipated by 2027 and an interim analysis planned after 40% of progression-free survival events occur. This positive clinical development for motixafortide, which is already approved in the U.S. as APHEXDA for stem cell mobilization in multiple myeloma, has triggered a substantial market reaction, with BLRX shares surging 81.96% to $6.97 on the Nasdaq. The company's CEO, Philip Serlin, emphasized the potential of this regimen to reshape the tumor microenvironment and improve outcomes in a notoriously difficult-to-treat cancer.

Key Decisions for Investors

• Consider the significant upside potential demonstrated by the Phase 2 PDAC data for motixafortide, evidenced by the 81.96% stock surge, while acknowledging the long development timeline with full trial enrollment expected by 2027.
• Closely monitor upcoming catalysts, particularly the interim analysis from the expanded randomized Phase 2 trial and patient enrollment milestones, as these will be critical validation points for the drug's efficacy and market potential.
• Recognize that while APHEXDA's existing approval offers a revenue base and some operational de-risking, the primary driver for recent valuation changes and future growth prospects currently hinges on the success of motixafortide in the substantially larger and higher unmet need PDAC market.
• Factor in the inherent risks and potential for significant volatility associated with clinical-stage biopharmaceutical investments, where outcomes of further trial phases and subsequent regulatory reviews can drastically impact share price and company valuation.